

Original article

Risk Factors for Mortality in 272 Patients With Lung Transplant: A Multicenter Analysis of 7 Intensive Care Units



Jordi Rello^{a,b,c,d,*}, Irene Bello^{a,b,k}, Rosario de Vicente^e, Ana Hermira Anchuelo^f,
María Ángeles Ballesteros^g, Reyes Iranzo^h, Luzdivina Rellánⁱ, Jordi Riera^{a,b}, Juan Carlos Robles^j,
EMPRET Study investigators¹

^a Vall d'Hebron University Hospital, Lung Transplant Team, Barcelona, Spain

^b Vall d'Hebron Research Institute (VHIR), Barcelona, Spain

^c CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III (CIBERES), Madrid, Spain

^d Medicine Department, Universitat Autònoma de Barcelona, Spain

^e Anesthesiology Department, Hospital Universitario La Fe, Valencia, Spain

^f Anesthesiology Department, Hospital Doce de Octubre, Madrid, Spain

^g Critical Care Dept, "Marqués de Valdecilla" University Hospital, Santander, Spain

^h Anesthesiology Department, Hospital Puerta de Hierro, Madrid, Spain

ⁱ Anesthesiology Department, Complejo Hospitalario Universitario de A Coruña, Spain

^j Critical Care Department, Hospital Reina Sofía, Córdoba, Spain

^k Surgical Department, Universitat Autònoma de Barcelona, Spain

ARTICLE INFO

Article history:

Received 27 October 2016

Accepted 8 December 2016

Available online 27 February 2017

Keywords:

Transplant donors

COPD

Postoperative critical care

Pulmonary graft dysfunction

Procalcitonin

ABSTRACT

Background: One-year survival in lung transplant is around 85%, but this figure has not increased in recent years, in spite of technical improvements.

Methods: Retrospective, multicenter cohort study. Data from 272 eligible adults with lung transplant were recorded at 7 intensive care units (ICU) in Spain in 2013. The objective was to identify variables that might help to guide future clinical interventions in order to reduce the risk of death in the postoperative period.

Results: One patient (0.3%) died in the operating room and 27 (10%) within 90 days. Twenty (7.4%) died within 28 days, after a median of 14 ICU days. Grade 3 pulmonary graft dysfunction was documented in 108 patients, of whom 21 died, compared with 6 out of 163 without pulmonary graft dysfunction ($P < .001$). At ICU admission, non-survivors had significantly lower ($P = .03$) median PaO₂/FiO₂ (200 mmHg vs 280 mmHg), and the difference increased after 24 hours (178 vs 297 mmHg, $P < .001$). Thirteen required extracorporeal membrane oxygenation, and 7 (53.8%) died. A logistic regression model identified pulmonary graft dysfunction (OR: 6.77), donor age > 60yr (OR: 2.91) and SOFA > 8 (OR: 2.53) as independent predictors of 90-day mortality. At ICU admission, higher median procalcitonin (1.6 vs 0.6) and lower median PaO₂/FiO₂ (200 vs 280 mmHg) were significantly associated with mortality.

Conclusion: Graft dysfunction remains a significant problem in lung transplant. Early ICU interventions in patients with severe hypoxemia or high procalcitonin are crucial in order to lower mortality.

© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Abbreviations: CMV, Cytomegalovirus; ICU, Intensive Care Unit; LT, lung transplant; SLT, single lung transplant; BLT, bilateral lung transplant; PGD, primary graft dysfunction; ISHT, The International Society for Heart and Lung Transplantation; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; PCT, Procalcitonin; CRP, C-reactive protein; BAL, bronchoalveolar lavage.

* Corresponding author.

E-mail address: jrello@crips.es (J. Rello).

¹ EMPRET Study Investigators detailed in Appendix 1.

Factores de riesgo de mortalidad en 272 pacientes sometidos a trasplante pulmonar: análisis multicéntrico de 7 unidades de cuidados intensivos

R E S U M E N

Palabras clave:

Donante pulmonar
EPOC
Postoperatorio cuidados intensivos
Disfunción del injerto pulmonar
Procalcitonina

Introducción: La supervivencia anual del trasplante de pulmón está alrededor del 85% y este porcentaje no se ha incrementado recientemente, a pesar de mejoras técnicas.

Métodos: Estudio de cohortes, multicéntrico, retrospectivo. Se recogieron datos de 272 adultos con trasplante de pulmón en 7 unidades de cuidados intensivos españolas en 2013. El objetivo fue identificar variables que pudieran ser de utilidad para guiar futuras intervenciones clínicas para disminuir el riesgo de fallecer en el postoperatorio.

Resultados: Un paciente (0,3%) falleció en quirófano y 27 (10%) a los 90 días. Veinte (7,4%) fallecieron en 28 días, después de una mediana de 14 días en unidad de cuidados intensivos. La disfunción primaria grado 3 se documentó en 108 pacientes, de los cuales 21 fallecieron, comparado con 6 de 163 sin disfunción primaria grado 3 ($p < 0,001$). Al ingreso en unidad de cuidados intensivos, los no supervivientes mostraban una significativa menor mediana ($p = 0,03$) de PaO₂/FiO₂ (200 vs. 280 mmHg); esta diferencia se incrementó a las 24 h (178 vs. 297 mmHg, $p < 0,001$). Trece requirieron oxigenación con membrana extracorpórea (53,8%) y 7 fallecieron. Un modelo de regresión logística múltiple identificó la disfunción primaria grado 3 (OR: 6,77), edad donante > 60 años (OR: 2,91) y SOFA > 8 (OR: 2,53) como predictores independientes ($p < 0,05$) de mortalidad a los 90 días. En el ingreso en unidad de cuidados intensivos, una mediana de procalcitonina plasmática superior (1,6 vs. 0,6 ng/mL) e inferior de PaO₂/FiO₂ (200 vs. 280 mmHg) se asociaron independientemente ($p < 0,05$) con la mortalidad.

Conclusión: La disfunción primaria del injerto continúa siendo un problema significativo en el trasplante pulmonar. Las intervenciones precoces dirigidas a mejorar la hipoxemia o la identificación de elevación de procalcitonina representan oportunidades para disminuir la mortalidad.

© 2017 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Adult patients undergoing primary lung transplantation have unadjusted survival rates of 89% at 3 months, 80% at 1 year, 65% at 3 years, 54% at 5 years and 31% at 10 years.¹ The most frequently reported causes of death within the first 30 days are graft failure and non-cytomegalovirus (CMV) infections. Over the first year post-transplant, non-CMV infections are the major cause of death. After this time, bronchiolitis, graft failure, non-CMV infections and malignancy become important contributors to mortality. The primary objective of this study was to improve our understanding of the interaction between donor variables, recipients, surgical conditions, and immediate postoperative management variables and their effect on ICU survival in patients with LT. The secondary objective was to identify possible biomarkers of mortality in the immediate postoperative period.

Methods

This is an analysis of a specific database which recorded all lung transplants performed in 2013 in Spain. Only adult patients who survived the intervention and for whom complete donor and recipient data were available were eligible for analysis of prognostic factors. This multicenter study was performed at 7 large general referral university hospitals (>700 beds) with active lung transplant programs. Ethical approval was obtained and the need for informed consent was waived at each center due to the observational nature of the study. All cases were recorded continuously.

Definitions

The APACHE (Acute Physiology And Chronic Health Evaluation) II score was designed to measure severity of disease in adult patients admitted to intensive care units.² It generates a point score ranging from 0 to 71 based on 12 physiological variables (including PaO₂, respiratory rate, heart rate, hematocrit and creatinine), age, and underlying health. The SOFA (Sequential Organ Failure Assessment) score is a composite score comprising 6 items: the

respiratory, coagulation, hepatic, cardiovascular, renal and neurological systems. It is used to track patient status during ICU stay and to establish the extent of organ function or failure.³

Pulmonary graft dysfunction (PGD) severity was graded according to the International Society for Heart and Lung Transplantation (ISHLT) consensus,⁴ using the partial pressure of arterial oxygen (PaO₂) to fraction of inspired oxygen (FiO₂) ratio. Grade 3 PGD was defined as a PaO₂/FiO₂ ratio of <200 mmHg.

Pneumonia was defined as new or progressive radiographic opacity, $\geq 10^4$ colony forming units·mL⁻¹ in bronchoalveolar lavage (BAL) fluid and at least 2 of the following: fever >38 °C, leukocytosis ($\geq 10,000$ cells mm⁻³) or leukopenia (<4000 cells mm⁻³) plus purulent secretions.⁵ Acute rejection was determined using the ISHLT consensus.^{6,7}

Biomarkers

Blood samples were collected in sterile ethylenediaminetetraacetic acid tubes (Vacutainer; Becton Dickinson, Cockeysville, MD). Tubes were immediately centrifuged at 915,642×g for 10 min at 48 °C, and serum was kept refrigerated at -80 °C until assayed. Plasma procalcitonin serum concentration (PCT) was determined by immunofluorescent assay, using an automated sandwich-type immunoanalysis (Thermo Scientific™ BRAHMS™ KRYPTOR™; Hennigsdorf, Germany) with TRACE (Time-Resolved Amplified Cryptate Emission) technology.

Statistical Analysis

All comparisons were unpaired. All tests of significance were two-tailed, and *P* values of .05 or less were regarded as indicating statistical significance. Continuous variables were compared using the Student's *t* test or ANOVA for normally distributed variables, and the Mann-Whitney *U* or Kruskal-Wallis test for non-normally distributed variables. The chi-square or Fisher's exact test was used to compare categorical variables. Values were expressed as medians (25th–75th percentile) (continuous variables) or as a frequency

of occurrence in the group from which they were derived (categorical variables).

Multivariate stepwise logistic regression was performed with 90-day (and 28-day) mortality being the dependent variables. Variables found in less than 10% of the sample were not entered in the multivariate models to avoid instability. All remaining covariates which were statistically significant at 0.05 in the univariate analysis were included in the model. A second model with 28-day mortality was also assessed. All statistical analyses were performed using SPSS, version 21.0 for Windows (SPSS Inc., Chicago, IL).

Results

Two hundred and eighty-five lung transplants were performed over the study period. One hundred forty-nine (54.8%) bilateral and 123 (45.2%) unilateral transplants were eligible for the study. One patient (0.3%) died in the operating room, and was excluded from analysis. Twenty-seven (10.8%) died within 90 days. Twenty (7.4%) died within 28 days after a median of 14 ICU days. Two hundred and thirty-eight survived and were discharged from the ICU after a median of 7 days. Mean age was 53.2 years, and 165 (61.3%) were males. Median body mass index was 25.0. Interstitial (43.4%), obstructive (40.4%) and suppurative diseases (15.8%) were the main underlying conditions. Twelve (4.4%) patients had primary pulmonary hypertension. Chronic bacterial colonization was documented in 104 (38.5%). With the exception of donor age (60-yr cut-off point), none of the variables were significantly associated with mortality.

In donors, median ICU stay was 2 days, and many donor variables were associated with overall mortality: non-survivors had similar donor age (median 54.1 vs 50.0 yr), PaO₂/FiO₂ ratio (median 447.5 vs 450 mmHg), smoking history (12.8% vs 9.8%), diabetes (8.3% vs 8.7%), cause of death, presence of opacities in chest radiograph (9.6% vs 10.9%), and normal bronchoscopy (89.1% vs 89.7%). In donors aged over 60 years (24.4%), 90-day mortality was significantly higher (16.6% vs 8.2%).

Regarding surgical issues, no significant differences were reported for ischemia time (320 vs 345 min), use of cardiopulmonary bypass (12.2% vs 10%) or median surgical time (6.0 vs 6.3 h). Significantly higher mortality was recorded in the 89 (32.7%) patients who underwent posterolateral thoracotomy (OR: 2.65, 95%CI 1.20–5.85). Only 3 patients required lobectomy due to discordant size, one of whom died. Several centers in our study perform different thoracotomies for single and bilateral lung transplant (SLT and BLT respectively). One site carried out 2 anterolateral thoracotomies for BLT, and another used clamshell thoracotomy; due to this variability, anterolateral thoracotomy was not considered a mortality factor. Basiliximab was prescribed as an induction immunosuppressor in 106 (30.1%) patients, and was associated with a trend toward lower mortality (OR: 0.41, 95%CI 0.16–1.06). Re-intervention after ICU admission was required in 25 (9.3%) patients; this subset presented increased mortality (32%) with OR: 5.55 (95%CI 2.12–14.52).

Median APACHE II score (24 vs 17) at ICU admission was significantly higher in non-survivors (OR: 1.12, 95%CI 1.06–1.19), as was median SOFA score (7 vs 5); OR: 1.14, 95%CI 1.03–1.29). The univariate analysis found that norepinephrine (>0.5 mcg/kg/min) support after the first 24 h had an OR of mortality of 5.87 (95%CI: 2.4–14.37). Grade 3 PGD was documented in 108 patients (39.9%), 21 of whom died, compared with 6 of 163 without grade 3 PGD ($P<.001$). Thirteen were supported by extracorporeal membrane oxygenation and 7 (53.8%) died. An association between days on mechanical ventilation and death was documented (OR: 1.04 per day; 95%CI 1.02 vs 1.07). Sixty-seven patients (24.8%) underwent tracheostomy. No significant differences were documented between mortality and

diaphragmatic paralysis (9.8% vs 10%). Re-intubation was more frequent in patients who died (15.6% vs 9.2%, $P<.05$), and was reported in 18.8% of the cohort. Acute rejection therapy was started in 24 (16.6%) patients, being confirmed in half of them by biopsy. Renal replacement therapy was used in only 22 patients (8.1%) but this cohort had a mortality rate of 40.9%, with an OR of mortality of 8.88 (95%CI 3.35–23.5). A summary of the univariate analyses of postoperative (90-d) mortality is detailed in [Table 1](#).

APACHE II score, SOFA score, recipient age and grade 3 PGD were assessed in a multivariate stepwise logistic regression analysis. The model identified grade 3 PGD (OR 7.18, 95%CI 2.49–26.05), SOFA > 8 (OR 2.86, 95%CI 0.81–8.85), and age > 60yr (OR: 2.64, 95%CI 0.94–7.16) as independent predictors of 90-day mortality.

The same variables were entered in a second logistic regression model, which identified grade 3 PGD (OR: 6.77; 95%CI 2.72–19.46), donor age > 60yr (OR: 2.91; 95%CI 7.07–1.18) and SOFA > 8 (OR 2.53, 95%CI 0.80–7.26) as independent predictors of 28-day mortality.

At ICU admission, non-survivors had significantly lower ($p=0.03$) median PaO₂/FiO₂ (200 mmHg vs 280 mmHg); the difference increased after 24 h (178 vs 297 mmHg, $P<.001$). Using >300 mmHg as a breakpoint, an OR of mortality of 0.30 (95%CI 0.12–0.78) was estimated. In contrast, C-reactive protein (CRP) (OR: 1.00; 95%CI 0.99–1.01) and lactate at ICU admission (OR: 1.01; 95%CI 0.90–1.08) did not show any association with mortality. However, non-survivors had significantly higher ($p=0.03$) median PCT (1.6 vs 0.6) at ICU admission, with the difference increasing after 24 h (5.4 vs 1.8, $P=.020$). Using PCT > 2.0 as the cut-off point, an OR of mortality of 2.05 (95%CI 0.79–5.34) was estimated.

Discussion

To the best of our knowledge, this is the first multicenter study to assess prognostic factors in the early postoperative period following lung transplant in Spain. In this large cohort, we demonstrated an independent association between PGD, donor age above 60-yr or SOFA score >8 with early mortality after lung transplant. Non-survivors had higher hypoxemia and higher PCT levels (in contrast to lactate or CRP) at ICU admission, identifying patients at high risk of death.

The univariate analysis indicated an increased risk of death with the use of posterolateral thoracotomy, which is a surrogate of single lung transplant. PGD, which is a risk factor for mortality, has been associated with SLT.⁸ In contrast, other studies did not report a statistical association between PGD and SLT.^{9–12} Our findings are in line with the ISHLT registry,¹ which found that SLT had worse survival than BLT. Our univariate analyses also showed that recipients with high APACHE II score and SOFA score >8 had a higher risk of mortality at 90 days. Oliveira et al.¹³ found that neither score had a better than average ability to predict hospital mortality in lung transplant recipients, and did not support their use in critically ill transplant patients. Arango et al.¹⁴ reported that although higher APACHE II scores were associated with prolonged mechanical ventilation and tracheotomy requirement, there was no association with higher rates of mortality or poor graft function. In our multivariate analysis, SOFA score >8 was associated with a 14% higher 90-day mortality, and in contrast to the APACHE II score, remained independently associated with death.

Graft failure is the main cause of death within the first 30 days after lung transplant and the second cause in the first year.¹ In our cohort, grade 3 PGD was present in over one-third of the recipients. We found grade 3 PGD to be a strong independent risk factor of mortality in ICU (OR 6.32) and the only independent variable that was susceptible to alteration by intervention measures. This finding is consistent with previous reports¹⁵ of a relationship between severe PGD and early mortality. In our cohort, grade 3 PGD at

Table 1
Univariate Analysis of 90-day Mortality.

	Survivors (n=244)	Non-surv (n=28)	P value
Recipient			
SLT VS BLT (%)	87	12	.229
Median age (years)	57	55	.769
Gender (%)			.730
Man	88.5	11.5	
Woman	91.3	8.7	
BMI	24.4 (14.1–35.2)	25.3 (19.1–29.8)	.185
Underlying disease (%)			
Obstructive	90.9	9.1	.684
Interstitial	89.8	10.2	1
Suppurative	86	14	.411
PH	91.7	8.3	1
Chronic bacterial colonization (%)	13.5	86.5	.219
Donor			
Median age (years)	50	54.5	.200
Gender (%)			1
Man	90.2	9.8	
Woman	89.5	10.5	
DM (%)	8.7	8.3	1
Smoking exposure (%)	9.8	12.8	.596
Cause of death (%)			.471
CET	20.9	22.2	
Stroke	66.5	74.1	
Other	12.6	3.7	
Chest-X rays (%)			.717
Normal	86.8	88.5	
Opacities	7.7	3.8	
Other	5.6	7.7	
Fibrobronchoscopy			.375
Normal	81.5	82.4	
Secretions	13.4	5.9	
Others	5.1	11.8	
Median PaO ₂ /FiO ₂ , mmHg	447.5	450	.710
Mean ICU days	2.9±4.0	2.7±2.5	.737
Surgery			
Anterior thoracotomy (%)	12.6	4.9	.079
Posterolateral thoracotomy (%)	7.1	16.9	.018*
Clamshell thoracotomy (%)	11.4	8.8	.548
Lung resection (%)	10	33.3	.279
Mean time (hours)	6.3 (2.1–12.8)	6.4 (3.3–12)	.901
CPB (%)	10	12.2	.588
Ischemia time (min)	351.6±110.1	312.3±64.3	.011*
Units PRBC	1.5 (0–20)	2.4 (0–23)	.802
NE>0.5 mcg/kg/min (%)	7.5	15.3	.093
APACHE II score (Mean)	17.7±6.6	24.2±7.5	<.001*
SOFA score (Mean)	4.9±3.5	7.1±2.9	<.001*
Median CRP at ICU admission	2.1	5.0	.127
Median PCT at ICU admission	0.6	1.6	.033*
Lactic acid at ICU admission	3.3±5.1	3.6±3.0	.332
Vasoactive drugs at ICU admission (%)	7.1	14.1	.085
PaO ₂ /FiO ₂ at ICU admission	286.8±130.4	227.9±141.9	.032*
Median CRP at 24 h	18.5	43	.139
Median PCT at 24 h	9.9 (0–340)	10.7	.02*
NE > 0.5 mcg/kg/min 24 h (%)	4.6	22.2	<.001*
PaO ₂ /FiO ₂ at 24 h, mmHg	299.7 (98–590)	219 (60–502)	<.001*
MV period (days)	6.7 (0–41.6)	14.6 (0.8–41.6)	<.001*
Re-intubation (%)	9.2	15.6	.34
Tracheostomy (%)	5.4	23.9	<.001*
Phrenic paralysis (%)	10.0	9.8	1
Grade 3 PGD (%)	3.7	19.4	<.001*
Respiratory infection (%)	6.2	16.8	.009*
Biopsy confirmed acute rejection (%)	3.2	8.8	.154
RRT (%)	7.2	40.9	<.001*
Surgery after ICU admission (%)	7.8	32	.001*
Induction with basiliximab (%)	12.7	5.7	.063
Median ICU stay (days)	7	14	.106

BLT: bilateral lung transplant; BMI: body mass index; CBP: cardiopulmonary bypass; CET: craneoencephalic trauma; CRP: C-reactive protein; DM: diabetes mellitus; PCT: procalcitonin hormone; PGD: primary graft dysfunction; PH: pulmonary hypertension; PRBC: packed red blood cells; MV: mechanical ventilation; NE: norepinephrine; RRT: renal replacement therapy; SLT: single lung transplant.

Data shown as percentages, median or mean (range).

* P<.05.

72 h remained an important factor for mortality (OR 6.48; 95%CI 1.47–38.44).

Our results have implications for clinical practice and further research. Our findings in lung transplant are consistent with previous studies in other organ transplants,^{6,7,13} and support the use of the SOFA score over the APACHE II score. Excepting age, other donor variables did not influence outcomes. Indeed, grade 3 PGD was identified as the main variable associated with death, and our findings suggest that efforts should be targeted at preventing its development. Early ICU interventions in patients with severe hypoxemia or high PCT (rather than lactate or CRP) are crucial in order to reduce mortality. In lung transplant, biomarkers may require a different cut-off point than for sepsis, due to surgical injury. The optimal cut-off point for biomarkers was estimated based on Younder index values.¹⁶ In our cohort, PCT above 2 was associated with a two-fold increase in the risk of death. Some early biomarkers (oxygenation and PCT) helped identify differences in risk of death within 24 h of surgery. This represents an opportunity for early identification of high-risk patients. Improved initial treatment in the ICU population may have an impact on outcome, particularly in the subset with grade 3 PGD. Further research into the identification of newer biomarkers, intra-operative biomarkers and postoperative breakpoints for Grade 3 PGD and mortality is now recommended.^{17,18}

While our study is multi-center and does not suffer from the impact of secular trends (all patients from a single year, 2013), other limitations should be mentioned. For instance, we cannot assess data such as biomarkers for all patients, exposing the study to a potential selection bias. Indeed, bias inherent to the retrospective design were the main limitations of the study. Each center has different protocols, case-mix, experience, number of transplants, and resources, being associated with high variability. This problem is exacerbated by patient heterogeneity, non-protocolized management (e.g., criteria for biopsy, use of ECMO, empiric pulses of steroids) and variable immunosuppression regimens or surgical approach, and this compromises the robustness of the analysis. Some variables were significantly associated with a low number of deaths, and there may have been a type II statistical error. Absolute mortality at 90 days is 27 patients; although the denominator is substantial (and multicenter), this means that all of the (many) analyses relate to only 27 patients. Larger sample sizes would identify additional prognostic factors which remain hidden in our study. In addition, 2 key risk factors (age, admission hypoxemia) are not necessarily amenable to meaningful intervention. The strengths of this study are that the cohort included all patients who underwent lung transplant within 1 year in Spain, and that patients were followed-up for 90 days after ICU discharge. Early measure of procalcitonin was able to identify patients requiring better management due to high risk of death.

Conclusions

Our findings indicate that Grade 3 PGD is the main variable associated with death. The use of early biomarkers within 24 h of surgery, such as oxygenation and PCT, can help differentiate patients in terms of risk of death. Thus, improved initial management in the ICU population may have an impact on outcome, particularly in the subset with grade 3 PGD.

Authorship

The study was designed by JCR and JRe. AHA, ELL, OG, JR, LR, RV, MB, EM, MS, MTRR, PRR and JCR reported patients. JCR coordinated and managed the database. JRe and IB wrote the first draft. The

remaining authors revised the manuscript and approved the final version

Conflicts of Interest

JR has received funding for travel or speaker's fees, and has served on scientific advisory boards for Pfizer Inc, Roche, Merck, Gilead Sciences, TermoFisher and Astellas Pharma Inc. The other authors have no conflicts of interest to declare.

Funding

The study was funded in part by CIBERES (InstitutoSalud Carlos III; Madrid), FISS 14/0114 and by an unrestricted research grant (PLUTO) from Astellas.

Acknowledgements

We would like to thank Luis Miguel Molinero Casares (AlceIngeniería, Valencia) for conducting the statistical analyses, and Michael Maudsley for help with the English.

Appendix A. APPENDIX 1: EMPRET Study Investigators

Ana Hermira-Anchuelo, Elisabeth Coll, Eloísa López-Lopez, Olga González-González, Teresa Pont, Cristófer Mazo, Jordi Riera, Irene Bello, Luzdivina Rellan, Rosario de Vicente, Ma Angeles Ballesteros, Eduardo Miñambres, Margarita Sanchez, María Teresa Rey-Rilo, Pablo Rama-Maceiras, Juan Carlos Robles, Jordi Rello.

References

- Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Adult Lung and Heart–Lung Transplant Report—2015; focus Theme: retransplantation. *J Heart Lung Transpl.* 2015;10:1264–77.
- Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. *Crit Care Med.* 1981;591–7.
- Elsayed FG, Sholkamy AA, Elshazli M, Elshafie M, Naguib M. Comparison of different scoring systems in predicting short-term mortality after liver transplantation. *Transpl Proc.* 2015;47:1207–10.
- Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. *J Heart Lung Transpl.* 2005;24:1454–9.
- ATS. IDSA Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med.* 2005;171:388–416.
- Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, et al. The 2013 international society for heart and lung transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. *J Heart Lung Transpl.* 2013;32:1147–62.
- Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. *J Heart Lung Transpl.* 2007;26:1229–42.
- Kuntz CL, Hadjiliadis D, Ahyia VN, Kotloff RM, Pochettino A, Lewis J, et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study. *Clin Transpl.* 2009;23:819–30.
- Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, et al., Lung Transplant Outcomes Group. Clinical risk factors for primary graft dysfunction after lung transplantation. *Am J Respir Crit Care Med.* 2013;187:527–34.
- Felten M-L, Sinaceur M, Treilhaud M, Roze H, Mornex J-F, Pottecher J, et al. Factors associated with early graft dysfunction in cystic fibrosis patients receiving primary bilateral lung transplantation. *Eur J Cardiothorac Surg.* 2012;41:686–90.
- Liu Y, Liu Y, Su L, Jiang S. Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis. *PLoS One.* 2014;9:e92773.
- Riera J. Primary graft dysfunction in lung transplant recipients: definition, pathogenesis and clinical management. *Minerva Pneumol.* 2014;53:137–53.
- De Oliveira VM, Brauner JS, Rodrigues Filho E, Susin RGA, Draghetto V, Bolzan ST, et al. Is SAPS 3 better than APACHE II at predicting mortality in critically ill transplant patients? *Clin (Sao Paulo, Brazil).* 2013;68:153–8.
- ArangoTomás E, Quero Ríos MI, Robles Arista JC, AlgarAlgar FJ, Wolf JJ, Alvarez Kindelan A, et al. Postoperative complications in the intensive care unit following

- lung transplantation in adults: results in University Hospital Reina Sofia. *Transpl Proc.* 2012;44:2663–5.
15. Cerón Navarro J, de AguiarQuevedo K, Jordá Aragón C, Peñalver Cuesta JC, MancheñoFranch N, Vera Sempere F, et al. Mortalidad perioperatoria del trasplante pulmonaren la enfermedad pulmonary obstructive crónica. *Med Clin (Barcel).* 2016;146:519–24.
 16. Youden WJ. Index for rating diagnostic tests. *Cancer.* 1950;3:32–5.
 17. Ruano L, Sacanell L, Roman A, Rello J. Role of biomarkers in the differential diagnosis of acute respiratory failure in the immediate postoperative period of lung transplantation. *Med Intens.* 2013;37:416–22.
 18. Riera J, Senna A, Cubero M, Roman A, Rello J. Primary graft dysfunction and mortality following lung transplantation: a role for proadrenomedullin plasma levels. *Am J Transpl.* 2016;16:634–9.